Table 1.
Baseline characteristics of the two cohort.
| Variables | Derivation cohort (n = 941) | Validation cohort (n = 396) |
|---|---|---|
| Age, years | 71 (60–81) | 70 (59–79) |
| Sex, n (%) | ||
| Male | 676 (71.8%) | 292 (73.7%) |
| Female | 265 (28.2%) | 104 (26.3%) |
| Smoke | 443 (47.1%) | 178 (44.9%) |
| Drink | 316 (33.6%) | 125 (31.6) |
| Cardiovascular disease | 651 (69.2%) | 225 (56.8%) |
| Cerebrovascular disease | 381 (40.5%) | 173 (43.7%) |
| Diabetes | 231 (24.5%) | 117 (29.5%) |
| SOFA score | 6 (4, 8) | 6 (4, 8) |
| APACHE II score | 18 (13, 22) | 17 (12, 23) |
| Respiratory rate, cycles/min | 23 (20, 29) | 22 (20, 28.8) |
| Systolic blood pressure, mm Hg | 122 (103.5, 142) | 120 (103, 145) |
| Diastolic blood pressure, mm Hg | 70 (60, 81) | 68 (60, 78) |
| P/F, mm Hg | 187.8 (131, 247.2) | 203.0 (141.1, 272.6) |
| WBC count, ×109/L | 11.2 (7.5, 15.3) | 11.5 (8.3, 16.5) |
| LYM count, ×109/L | 0.8 (0.5, 1.3) | 0.7 (0.5, 1.1) |
| N/L | 10.1 (6.1, 19.8) | 13.7 (7.7, 24.0) |
| HgB, g/L | 104 (87, 123) | 106 (90, 120) |
| Platelet count, ×109/L | 188 (125.5, 267) | 186 (123.2, 272.8) |
| TP, g/l | 56.2 (51, 61.1) | 56 (51.3, 60.1) |
| ALB, g/l | 29.2 (26.2, 32.2) | 30.2 (27.4, 33.6) |
| LDH, U/L | 341 (245, 515.5) | 321 (241.5, 466.2) |
| CRE, μmol/L | 61 (45, 93) | 63.5 (42, 108) |
| BUN, mmol/L | 9 (6, 14.2) | 10.0 (6.3, 15.1) |
| CRP, mg/L | 98.8 (46.1, 163.2) | 92.0 (42.3, 147.8) |
| PCT | 0.8 (0.2, 3.4) | 0.8 (0.2, 3.2) |
| Glu, mmol/L | 7.1 (5,5, 9.7) | 7.7 (6.3, 9.7) |
| D-dimmer, μg/mL | 2.8 (1.5, 5.4) | 3.1 (3.5, 6.5) |
| Lac, mmol/L | 1.6 (1.2, 2.1) | 1.6 (1.2, 2.2) |
| VD | 403 (42.8%) | 166 (42.0%) |
P/F, PaO2/FiO2; WBC, white blood cell; LYM, lymphocyte; N/L, Neutrophils/lymphocyte; HgB, hemoglobin; TP, total protein; ALB, albumin; LDH, lactate dehydrogenase; CRE, creatinine; BUN, blood urea nitrogen; Glu, glucose,; Lac, lactate; VD, vasoactive drug.